Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… supports ProQR’s strategic focus on its proprietary Axiomer ® RNA editing technology platform and continued … of ProQR. “We look forward to continuing to advance our Axiomer RNA editing platform, with an initial focus on … is pioneering a next-generation RNA technology called Axiomer ® , which uses a cell’s own editing machinery called …